Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 8/20 | 0.66 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564837 | 1.00 | CTSC (0.66) | CTSCCTSBCTSKCYP1A2CYP3A4 | |
| SCHEMBL5567253 | 0.96 | CTSC (0.64) | CTSCCTSBCTSKCYP1A2CYP3A4 | |
| SCHEMBL5567254 | 0.96 | CTSC (0.64) | CTSCCTSBCTSKCYP1A2CYP3A4 | |
| SCHEMBL7872411 | 0.84 | CTSC (0.71) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL8530955 | 0.83 | FAAH (0.55) | CTSCPSMB5FAAHSMN1; SMN2 | |
| SCHEMBL10889436 | 0.82 | FAAH (0.57) | PSMB5FAAH | |
| SCHEMBL10890368 | 0.82 | FAAH (0.57) | PSMB5FAAH | |
| SCHEMBL10889905 | 0.82 | FAAH (0.57) | PSMB5FAAH | |
| SCHEMBL10889442 | 0.82 | FAAH (0.57) | PSMB5FAAH | |
| SCHEMBL10887549 | 0.82 | FAAH (0.57) | PSMB5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183443-B2 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2007-02-27 | — | — | US | disclosed |
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2005-09-29 | — | — | US | disclosed |
| EP-1492760-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP Assets B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087033-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | WO | disclosed |
| EP-1352894-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP Assets B.V. (NL) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | ADH1C, ADH1A, ADH5 | CTSC 899/4885CTSB 3846/4885CTSK 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.